LOR Share Price

Open 0.52 Change Price %
High 0.52 1 Day -0.02 -3.85
Low 0.49 1 Week 0.00 0.00
Close 0.50 1 Month 0.00 0.00
Volume 213228 1 Year 0.00 0.00
52 Week High 77.22
52 Week Low 42.24
LOR Important Levels
Resistance 2 0.53
Resistance 1 0.52
Pivot 0.50
Support 1 0.48
Support 2 0.47
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BTO 3.19 -5.62%
BTO 3.19 -5.62%
PLI 2.00 4.71%
PLI 2.00 4.71%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
DA-A 0.22 22.22%
INQ 4.08 21.79%
INQ 4.08 21.79%
CTU-A 0.25 19.05%
MM 0.07 16.67%
MM 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
LRT-UN 0.07 -22.22%
TLB 0.60 -16.67%
TLB 0.60 -16.67%
RKN 1.62 -12.43%
RKN 1.62 -12.43%
PWC 0.08 -11.11%
PWC 0.08 -11.11%
ORA 0.16 -11.11%
ORA 0.16 -11.11%
More..

Lorus Therapeutics Inc (TSE: LOR)

LOR Technical Analysis 1.5
As on 2nd Sep 2014 LOR Share Price closed @ 0.50 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.52 & Buy for SHORT-TERM with Stoploss of 0.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
LOR Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
LOR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.lorusthera.com
LOR Address
LOR
2 Meridian Road
Toronto, ON M9W 4Z7
Canada
Phone: 416-798-1200
Fax: 416-798-2200
Interactive Technical Analysis Chart Lorus Therapeutics Inc ( LOR TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Lorus Therapeutics Inc
LOR Business Profile
Lorus Therapeutics Inc., a biopharmaceutical company, engages in the discovery, research, and development of novel anticancer therapies in Canada. Its product pipeline includes LOR-253, an anticancer agent for the treatment of human cancers, including colon cancer and non-small cell lung cancer; IL-17E, an immunotherapy for various solid tumors, including human melanoma, pancreatic, colon, lung, ovarian, and breast tumor; and LOR-500 program to discover and develop potent and small molecule inhibitors of maternal embryonic leucine zipper kinase. The company’s development stage products also include LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor for the treatment of acute myeloid leukemia; and Virulizin for various cancers, including breast, ovarian, and pancreatic cancers. In addition, its preclinical stage small molecules comprise LOR-220, a novel small molecule for drug-resistant bacterial infections. The company was formerly known as Imutec Pharma Inc. and changed its name to Lorus Therapeutics Inc. in November 1998. Lorus Therapeutics Inc. was founded in 1986 and is headquartered in Toronto, Canada.